Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB054828 plus paclitaxel as second-line therapy in recurrent/advanced gastric cancer with FGF/FGFR aberrations
KCT0003844Phase 2Terminated
- Sponsor
- Yonsei University Health System
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in gastric cancer (GC), sponsored by Yonsei University Health System. Started Oct 2019; status: terminated.
02
Drugs
pemigatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0003844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003844.